Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

Aeolus Pharmaceuticl

Healthcare US AOLS

0.0001USD
0.00(0%)

Last update at 2026-06-04T20:00:00Z

Day Range

0.00010.0001
LowHigh

52 Week Range

0.00010.0001
LowHigh

Fundamentals

  • Previous Close 0.0001
  • Market Cap0.02M
  • Volume100000
  • P/E Ratio-
  • Dividend Yield-%
  • Revenue TTM0.77M
  • Revenue Per Share TTM0.005
  • Gross Profit TTM -1.72100M
  • Diluted EPS TTM-

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2023-09-30 2022-09-30 2021-09-30 2020-09-30 2019-09-30
Type yearly yearly yearly yearly yearly
Date 2023-09-30 2022-09-30 2021-09-30 2020-09-30 2019-09-30
Income before tax - - - - -
Minority interest - - - - -
Net income - - - - -
Selling general administrative - - - - -
Selling and marketing expenses - - - - -
Gross profit - - - - -
Reconciled depreciation - - - - -
Ebit - - - - -
Ebitda - - - - -
Depreciation and amortization 0.17M 0.23M 0.24M 0.21M 0.17M
Non operating income net other - - - - -
Operating income - - - - -
Other operating expenses - - - - -
Interest expense - - - - -
Tax provision - - - - -
Interest income - - - - -
Net interest income - - - - -
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense - - - - -
Total revenue - - - - -
Total operating expenses - - - - -
Cost of revenue - - - - -
Total other income expense net - - - - -
Discontinued operations - - - - -
Net income from continuing ops - - - - -
Net income applicable to common shares - - - - -
Preferred stock and other adjustments - - - - -
Breakdown 2023-09-30 2022-09-30 2021-09-30 2020-09-30 2019-09-30
Type yearly yearly yearly yearly yearly
Date 2023-09-30 2022-09-30 2021-09-30 2020-09-30 2019-09-30
Total assets - - - - -
Intangible assets - - - - -
Earning assets - - - - -
Other current assets - - - - -
Total liab - - - - -
Total stockholder equity - - - - -
Deferred long term liab - - - - -
Other current liab - - - - -
Common stock - - - - -
Capital stock - - - - -
Retained earnings - - - - -
Other liab - - - - -
Good will - - - - -
Other assets - - - - -
Cash - - - - -
Cash and equivalents - - - - -
Total current liabilities - - - - -
Current deferred revenue - - - - -
Net debt - - - - -
Short term debt - - - - -
Short long term debt - - - - -
Short long term debt total - - - - -
Other stockholder equity - - - - -
Property plant equipment - - - - -
Total current assets - - - - -
Long term investments - - - - -
Net tangible assets - - - - -
Short term investments - - - - -
Net receivables - - - - -
Long term debt - - - - -
Inventory - - - - -
Accounts payable - - - - -
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - - - - -
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other - - - - -
Deferred long term asset charges - - - - -
Non current assets total - - - - -
Capital lease obligations - - - - -
Long term debt total - - - - -
Breakdown 2016-09-30 2015-09-30 2014-09-30 2013-09-30 2012-09-30
Type yearly yearly yearly yearly yearly
Date 2016-09-30 2015-09-30 2014-09-30 2013-09-30 2012-09-30
Investments - - - - -
Change to liabilities -0.64800M -0.37500M 0.73M -1.01100M 0.13M
Total cashflows from investing activities - - - - -
Net borrowings - 1.00M 1.00M 1.00M -
Total cash from financing activities 6.17M 1.02M 0.33M 3.56M 0.64M
Change to operating activities -0.16400M 0.41M 0.22M -0.53900M -
Net income -3.55800M -2.62800M -0.08000M -3.20800M 1.70M
Change in cash 3.06M -1.42300M 0.65M 0.59M -0.23700M
Begin period cash flow 0.09M 1.52M 0.87M 0.28M 0.52M
End period cash flow 3.15M 0.09M 1.52M 0.87M 0.28M
Total cash from operating activities -3.10900M -2.44300M 0.32M -2.97000M -0.87900M
Issuance of capital stock - - - - -
Depreciation 0.28M 0.28M 0.28M 0.00600M 0.00700M
Other cashflows from investing activities - - - - -
Dividends paid - - - - -
Change to inventory - - - - -
Change to account receivables 0.83M -0.02600M -1.18900M 0.41M 0.80M
Sale purchase of stock 2.00M 0.02M 0.33M -0.05800M -0.01800M
Other cashflows from financing activities -0.33500M -0.33500M -0.33500M -0.05800M -
Change to netincome 0.14M 0.18M 0.64M 1.37M -
Capital expenditures 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Change receivables 0.83M -0.02400M -1.18900M - -
Cash flows other operating 0.10M 0.00100M -0.00700M - -
Exchange rate changes - - - - -
Cash and cash equivalents changes 3.06M -1.42300M 0.65M - -
Change in working capital 0.02M 0.00500M -0.23200M -1.13900M 0.92M
Stock based compensation - - - - 0.57M
Other non cash items 0.43M 0.18M 0.64M 1.37M -4.06900M
Free cash flow -3.10900M -2.44300M 0.32M -2.97000M -0.87900M

Peer Comparison

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
AOLS
Aeolus Pharmaceuticl		 - -% 0.0001 - - 0.02 0.81 0.22 -0.0409
ZTS
Zoetis Inc		 0.47 0.59% 79.99 40.18 30.96 10.67 17.60 11.27 26.18
MKKGY
Merck KGaA ADR		 -0.54 1.67% 31.78 21.25 14.93 3.10 2.14 3.60 12.98
MKGAF
MERCK Kommanditgesellschaft auf Aktien		 - -% 163.71 21.73 14.95 3.16 2.15 3.56 12.82
GALDY
GALDERMA GROUP AG		 0.23 0.56% 40.81 74.21 41.67 8.64 5.55 9.15 42.22

Reports Covered

Stock Research & News

View All

Profile

Aeolus Pharmaceuticals, Inc., a biopharmaceutical company, develops a platform of novel compounds for use in biodefense, fibrosis, oncology, infectious, and central nervous system diseases in the United States. The company develops a class of catalytic antioxidant compounds as medical countermeasures against nuclear, radiological, and chemical weapons, as well as for diseases and disorders of the respiratory system, central nervous system, and oncology. Its lead compound includes AEOL 10150 that has completed two Phase I clinical trials, which is developed against the pulmonary sub-syndrome of acute radiation syndrome; and for use as a medical countermeasure for exposure to chemical vesicants and nerve agents. The company is also developing AEOL 11207 for the treatment of Parkinson's disease. Aeolus Pharmaceuticals, Inc. was founded in 1994 and is based in Mission Viejo, California.

Aeolus Pharmaceuticl

27800 Medical Center Rd, Mission Viejo, CA, United States, 92691

Key Executives

Name Title Year Born
Mr. John L. Mcmanus Chief Exec. Officer and Pres 1964
Mr. Christopher Stanley VP of Operations NA
Mr. John L. Mcmanus Chief Executive Officer and President 1964
Mr. Christopher Stanley Vice President of Operations NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to our Cookies Policy. For more information, read our Privacy Policy and Terms and Conditions